350229-29-7
350229-29-7
Chemical Structure
ABD-3001
- CAS No.: 350229-29-7
- Formula:C9H15NOS
- Molecular Weight:185.29
IUPAC Name: S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate
InChIKey: XFLSMXBNQSTUIY-UHFFFAOYSA-N
SMILES: O=C(SC)C#CC(C)(C)N(C)C
Biological Activity: ABD-3001 is an ALDH1 inhibitor. ABD-3001 induces costimulatory molecules, ER/protein homeostasis stress, and extracellular Calreticulin exposure compatible with immunogenic cell death. ABD-3001 can be used for research on acute undifferentiated leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ABD-3001 | 95.44% | ABD-3001 is an ALDH1 inhibitor. ABD-3001 induces costimulatory molecules, ER/protein homeostasis stress, and extracellular Calreticulin exposure compatible with immunogenic cell death. ABD-3001 can be used for research on acute undifferentiated leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Baier C, et al. ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML. Frontiers in immunology. 2026;17:1876637.
- [2]. Costello MP, et al. AML-312: ALDH-Inhibitor (ABD-3001) Plus Azacitidine-Venetoclax Induce MRD-Negative Remission in TP53 Double-Hit Acute Undifferentiated Leukemia Refractory to Flag-IDA-VEN. Clinical Lymphoma Myeloma and Leukemia. 2026 Aug 1;26:S456-7.
- [3]. Andrieu G P, et al. Harnessing ALDH1A2 vulnerability in T-cell acute lymphoblastic leukemia[J]. bioRxiv, 2025: 2025.03. 11.642712.
